Clinical-epidemiological profile, and treatment response in relation to associated atopic comorbidity in atopic dermatitis. Experience from the BIOBADATOP registry

Peris Espino, Vicente; Giménez Arnau, Anna Maria; Curto Barredo, Laia; Bertolín Colilla, Marta; Carrascosa Carrillo, José Manuel

doi:http://dx.doi.org/10.1016/j.ad.2025.02.014

Clinical-epidemiological profile, and treatment response in relation to associated atopic comorbidity in atopic dermatitis. Experience from the BIOBADATOP registry

License

Citation

Peris-Espino V, Munera-Campos M, Chicharro P, González Quesada A, Flórez Menéndez Á, de la Cueva Dobao P, et al. Clinical-epidemiological profile, and treatment response in relation to associated atopic comorbidity in atopic dermatitis. Experience from the BIOBADATOP registry. Actas Dermosifiliogr. 2025 Apr;116(4):T337-T348. DOI: 10.1016/j.ad.2025.02.014

Abstract

Background: Despite advances made in treatments for atopic dermatitis (AD), information on its impact and interaction with atopic comorbidities, such as asthma, rhinoconjunctivitis, and ocular disease is limited. This study aims to assess the clinical-epidemiological characteristics of patients with AD - treatment response included - while taking into consideration atopic comorbidities like these. Materials and methods: Data were analyzed from the multicenter BIOBADATOP registry (a prospective cohort of AD patients initiating systemic treatment). We conducted a descriptive analysis of the main characteristics collected in the registry in relation to atopic comorbidity. Results: We included a total of 509 patients, mostly adults (81.9%) with severe AD (73.7%). Patients with personal atopic comorbidity (64%) more frequently exhibited flexural dermatitis (89.7% vs. 81.5%), a higher mean of previous systemic treatments (1.6 vs. 1.3), and higher baseline values on the POEM scale (19.6 vs. 17.9). Patients with familial atopic comorbidity (40.7%) had a higher incidence of pediatric/adolescent patients (24.2% vs. 13.9%) and a history of allergic rhinoconjunctivitis (61.1% vs. 47.1%). No differences regarding treatment response were observed at the 6- and 12-month follow-ups based on the presence or absence of atopic comorbidities. Conclusions: Results suggest that a history of atopic comorbidity is associated with an early onset and persistent course of AD. Although no differences were reported in the short-term treatment response, further follow-up is required to better understand the impact of comorbidities on AD.